- The R&D program will focus on the proprietary Lexaria DehydraTECH delivery technology with the purpose of enhancing it further
- Results could contribute to new patent filings in the future; in addition, the program will examine more extensively the way DehydraTECH-enabled CBD outperforms generic CBD
- Lexaria-designed nanotech enhancements will also be included in the program
Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is launching its largest cannabinoid research and development program to date. The program consists of 11 separate animal studies, according to a company press release (http://cnw.fm/YZd5X).
The Lexaria in vitro study design was conceptualized six months ago. Laboratory test articles have been produced and meet or exceed required quality control thresholds. The program has moved on to the implementation stage, which includes testing for a variety of performance-enhancing variations of the company’s DehydraTECH.
The DehydraTECH trademarked delivery technology is patented for cannabidiol (CBD) and tetrahydrocannabinoid (THC). The technology has a wide scope of applications, with evidence gathered separately of an ability to cross the blood-brain barrier, which could lead to applications related to nervous system conditions like Alzheimer’s disease.
Through the research, Lexaria aims to enhance the DehydraTECH drug delivery platform even further, with optimization enhancement designed to improve the platform’s performance in next-generation formulations currently under development.
As per the official Lexaria announcement, the research and development program could contribute to additional patent filings in the future. Thus, the company has limited information about the study’s design for the time being. The primary aim of the research, however, is to determine the mechanisms by which DehydraTECH-enabled CBD outperforms generic CBD – a fact that has already been established through multiple trials.
DehydraTECH and the other Lexaria technologies are already disrupting the cannabis edibles industry. These developments reduce the undesirable taste of CBD products, eliminate the need for the addition of sweeteners (simplifying the creation of sugar-free options), increase absorption rates and reduce the time of positive effect onset.
Lexaria-designed nanotech enhancements will also be included among the research and development program subjects. In the beginning of 2018, Lexaria evaluated a number of nanotech emulsions for use with DehydraTECH. These nano emulsions are expected to be tested in combination with the DehydraTECH delivery system for the first time ever.
Various nanotech solutions are already available on the market. No other company, however, has come up with a combination of nano emulsions and a drug delivery platform that’s patented for use with cannabinoids. Lexaria representatives believe that the combination enhances the individual performance characteristics of both technologies.
DehydraTECH is a disruptive delivery technology platform that promotes healthier ingestion methods and lower dosages, while increasing overall effectiveness of lipophilic active molecules. Lexaria Bioscience Corp. has multiple patents pending in over 40 countries and already has patents granted in the U.S. and Australia for the utilization of its signature DehydraTECH technology. The technology increases intestinal absorption rates, allowing for more rapid delivery to the bloodstream of various orally administered bioactive compounds, such as cannabinoids, vitamins and non-steroid anti-inflammatory drugs.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000
For more information please visit https://www.cannabisnewswire.com and or https://CannabisNewsWire.News
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
